Skip to main content

Illumina Value Stock - Dividend - Research Selection


ISIN: US4523271090 , WKN: 927079

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

We are the global leader in sequencing- and array-based solutions for genetic analysis. Our products and services serve customers in a wide range of markets, enabling the adoption of genomic solutions in research and clinical settings. We were incorporated in California in April 1998 and reincorporated in Delaware in July 2000. Our principal executive offices are located at 5200 Illumina Way, San Diego, California 92122. Our telephone number is (858) 202-4500. Our customers include leading genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. Our portfolio of integrated systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. This portfolio addresses the range of genomic complexity, price points, and throughput, enabling customers to select the best solution for their research or clinical challenge. Over the past five years, we have made key acquisitions to provide our customers with more comprehensive sample-to-answer solutions and to enable our goal of becoming a leader in the clinical market. These include: GenoLogics Life Sciences Software Inc., a developer of industry-leading laboratory information management systems, in August 2015; Myraqa, Inc., a regulatory and quality consulting firm specializing in IVDs and companion diagnostics, in July 2014; NextBio, a provider of clinical and genomic informatics, in November 2013; Advanced Liquid Logic Inc., a developer of digital microfluidics and liquid handling solutions, in July 2013; Verinata Health, Inc., a provider of non-invasive tests for the early identification of fetal chromosomal abnormalities, in February 2013; and BlueGnome Ltd., a provider of cytogenetics and in vitro fertilization screening solutions, in September 2012. We also invest in early-stage companies that are pursuing promising genomics-related technologies. For example, GRAIL, Inc. (GRAIL), formed in January 2016, was created to develop a blood test for early-stage cancer detection, and Helix Holdings I, LLC (Helix) was established in 2015 to enable individuals to explore their genetic information by providing sequencing and services for consumers through third-party partners. GRAIL and Helix are consolidated variable interest entities. Source:
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Illumina Should Heed Carl Icahn, Give Up on Grail

Many of Illumina shareholders have grown increasingly frustrated with Chief Executive Francis deSouza’s pursuit of Grail. The decision to close the $7.1 billion acquisition in August 2021 despite regulators’ objections baffled many investors and is largely to blame for cutting the company’s market capitalization in half. Grail, which makes cancer-detection tests, lost about $600 million last year, cutting into Illumina’s profit.

Illumina Inc. stock outperforms market despite losses on the day

Shares of Illumina Inc. slipped 0.18% to $224.55 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...

Why Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

UPDATE 1-Carl Icahn urges Fed to keep fighting inflation after SVB collapse - FT

Activist investor Carl Icahn has urged the U.S. Federal Reserve to stay the course in the fight against the "disease of inflation" despite the failure of Silicon Valley Bank and two other banks last week, the Financial Times reported on Friday. "I think you have to stamp out the disease of inflation," Icahn told FT, ahead of Fed's rate-setting meeting next week in which the U.S. central bank is expected to raise its benchmark by 25 basis points. The activist investor also warned of stress beyond the financial sector, saying that many companies had wasted billions of dollars on flawed acquisitions and become over indebted in the process, the report said.

Carl Icahn urges Fed to keep fighting inflation ‘disease’ after SVB collapse

Activist investor Carl Icahn has urged the Federal Reserve to stay the course in the fight against the “disease of inflation” despite the failure of Silicon Valley Bank and two other banks last week. “I think you have to stamp out the disease of inflation,” Icahn told the Financial Times. Icahn’s comments come ahead of the Fed’s rate-setting meeting next week, with economists actively debating whether it will raise interest rates by 0.25 percentage points or take a pause following the SVB implosion.

Illumina Inc. stock underperforms Thursday when compared to competitors

Shares of Illumina Inc. slipped 1.40% to $224.95 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...

Buy This Magnificent Growth Stock Before It's Too Late

Bionano Genomics (NASDAQ: BNGO) appears to be in just that place -- at the start of its growth journey -- and it could be a great way to give your portfolio some additional upside potential. Bionano's claim to fame is its laboratory analyzer device for optical genome mapping, which it calls the Saphyr.

Icahn urges Illumina to unwind Grail deal, pushes ahead on proxy fight

Billionaire investor Carl Icahn is urging life sciences company Illumina Inc to divest cancer test developer Grail Inc and said on Wednesday that his director candidates will be best placed to pursue this goal.

Illumina (ILMN) Unveils Complete Long Reads Technology

Illumina's (ILMN) Complete Long Read Prep combines Illumina sequencing by synthesis chemistry with DRAGEN secondary analysis to provide WGS with more accuracy.

Illumina Inc. stock rises Wednesday, outperforms market

Shares of Illumina Inc. rose 1.00% to $228.15 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...